Q1 Earnings Forecast for NuCana Issued By William Blair

NuCana plc (NASDAQ:NCNA) – Investment analysts at William Blair issued their Q1 2026 earnings per share estimates for NuCana in a research report issued to clients and investors on Thursday, March 20th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for NuCana’s current full-year earnings is ($13.42) per share. William Blair also issued estimates for NuCana’s Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at ($0.01) EPS.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $2.11.

NuCana Price Performance

Shares of NCNA stock opened at $0.79 on Monday. The company’s fifty day moving average price is $0.96 and its two-hundred day moving average price is $1.51. The firm has a market capitalization of $2.09 million, a P/E ratio of -0.08 and a beta of 0.89. NuCana has a 12 month low of $0.69 and a 12 month high of $10.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new stake in shares of NuCana during the fourth quarter worth approximately $30,000. Schonfeld Strategic Advisors LLC acquired a new stake in NuCana during the fourth quarter worth $54,000. Two Sigma Securities LLC acquired a new stake in NuCana in the 4th quarter valued at $25,000. Finally, Virtu Financial LLC acquired a new stake in shares of NuCana in the fourth quarter valued at $48,000. 44.00% of the stock is currently owned by institutional investors.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.